1. Home
  2. CBNK vs CBIO Comparison

CBNK vs CBIO Comparison

Compare CBNK & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBNK

Capital Bancorp Inc.

N/A

Current Price

$42.10

Market Cap

560.3M

Sector

Finance

ML Signal

N/A

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

N/A

Current Price

$13.37

Market Cap

488.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CBNK
CBIO
Founded
1974
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
560.3M
488.1M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
CBNK
CBIO
Price
$42.10
$13.37
Analyst Decision
Hold
Strong Buy
Analyst Count
5
8
Target Price
★ $44.08
$31.50
AVG Volume (30 Days)
136.9K
★ 204.8K
Earning Date
10-26-2026
11-20-2026
Dividend Yield
★ 1.31%
N/A
EPS Growth
★ 60.85
N/A
EPS
★ 2.40
N/A
Revenue
N/A
★ $18,500.00
Revenue This Year
$8.98
N/A
Revenue Next Year
$10.68
$177.36
P/E Ratio
$17.82
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.40
$8.72
52 Week High
$44.76
$27.41

Technical Indicators

Market Signals
Indicator
CBNK
CBIO
Relative Strength Index (RSI) 58.96 47.21
Support Level $35.70 $10.25
Resistance Level N/A $13.54
Average True Range (ATR) 0.94 0.96
MACD -0.05 0.16
Stochastic Oscillator 40.77 35.66

Price Performance

Historical Comparison
CBNK
CBIO

About CBNK Capital Bancorp Inc.

Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage. The company generates majority revenue from the Commercial bank sector. Commercial Banking division focuses on providing personalized service to commercial clients throughout the operations supplemented by lending outside primary market as well as engaging in government guaranteed lending on a national basis.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: